Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and Mexico in the second half of 2025 as production capacity increases, its finance chief said on Monday.

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about Ozempic's and Mounjarno's patent cliffs. The scenarios in which Novo Nordisk and Eli Lilly are actually undervalued.

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new available vial doses.

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States.

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly diving into the opportunity to make anti-obesity products. This article looks into key players in the arena.

Doctor, doctor, give me the news, Hims & Hers Health (HIMS) has got bad case of the stock market blues. The San Francisco telehealth company could've used some strong medicine on March 6 when its shares took sick amid a court ruling and stepped up competition involving weight-loss drugs.

Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online to try to stave off competition from compounding pharmacies and rival Novo Nordisk .

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs.